RecruitingPhase 2Phase 3NCT05891769

99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

Evaluation of Patients With Suspected Parathyroid Adenoma and Negative or Equivocal 99mTc Sestamibi SPECT/CT Using 18F Fluorocholine PET/CT


Sponsor

Andrei Iagaru

Enrollment

100 participants

Start Date

Sep 27, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study compares two imaging tests — a standard nuclear medicine scan (SPECT/CT with sestamibi) and a newer PET scan (with fluorocholine) — to find overactive parathyroid glands in people with high calcium levels. **You may be eligible if...** - You are suspected to have a parathyroid adenoma (an overactive parathyroid gland causing high calcium) - Your standard sestamibi scan was negative or unclear - Your liver function is within acceptable limits - You can give written consent **You may NOT be eligible if...** - Your initial scan was clearly positive and surgery is already planned - You have liver problems (elevated bilirubin or liver enzymes) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG18Fluorocholine

18F Fluorocholine 5 mCi ± 20% administered intravenously.


Locations(1)

Stanford Hospital and Clinics

Stanford, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05891769


Related Trials